A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A review and recommendations for oral chaperone therapy in adult patients with Fabry disease ; volume:19 ; number:1 ; day:18 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
Orphanet journal of rare diseases ; 19, Heft 1 (18.1.2024), 1-13, 12.2024
- Urheber
-
Nowicki, Michał
Bazan-Socha, Stanisława
Błażejewska-Hyżorek, Beata
Kłopotowski, Mariusz M.
Komar, Monika
Kusztal, Mariusz A.
Liberek, Tomasz
Małyszko, Jolanta
Mizia-Stec, Katarzyna
Oko-Sarnowska, Zofia
Pawlaczyk, Krzysztof
Podolec, Piotr
Sławek, Jarosław
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-024-03028-w
- URN
-
urn:nbn:de:101:1-2406122112036.161361057749
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nowicki, Michał
- Bazan-Socha, Stanisława
- Błażejewska-Hyżorek, Beata
- Kłopotowski, Mariusz M.
- Komar, Monika
- Kusztal, Mariusz A.
- Liberek, Tomasz
- Małyszko, Jolanta
- Mizia-Stec, Katarzyna
- Oko-Sarnowska, Zofia
- Pawlaczyk, Krzysztof
- Podolec, Piotr
- Sławek, Jarosław
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data”
Hypertension in adult Fabry’s disease: is cardiotrophin-1 a diagnostic biomarker?
Pain in fabry disease: practical recommendations for diagnosis and treatment
Molekulare Chaperone
Co-chaperone interactions in the Hsp90 chaperone cycle
Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry
COVID-19 Pandemic: Oral Health Challenges and Recommendations
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data”
Hypertension in adult Fabry’s disease: is cardiotrophin-1 a diagnostic biomarker?
Pain in fabry disease: practical recommendations for diagnosis and treatment
Molekulare Chaperone
Co-chaperone interactions in the Hsp90 chaperone cycle
Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry
COVID-19 Pandemic: Oral Health Challenges and Recommendations
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data”
Hypertension in adult Fabry’s disease: is cardiotrophin-1 a diagnostic biomarker?
Pain in fabry disease: practical recommendations for diagnosis and treatment
Molekulare Chaperone
Co-chaperone interactions in the Hsp90 chaperone cycle
Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry
COVID-19 Pandemic: Oral Health Challenges and Recommendations